NeoGenomics Enters Into Testing Deal With Aurora Diagnostics

NeoGenomics has entered into an agreement with Aurora Diagnostics to provide molecular testing at its various testing sites throughout the United States. Under the terms of the agreement, the Fort Myers, Fla.-based NeoGenomics will provide molecular, fluorescence in situ hybridization (FISH), and immunohistochemistry testing at Aurora’s 19 anatomic pathology labs. “Our committee evaluated quality of testing, breadth and depth of services, information technology capabilities, managed care access, product development pipeline, and future partnership opportunities,” said Aurora Executive Vice President Bruce Walton, who added that several molecular labs were evaluated for a potential joint venture. The Palm Beach Gardens, Fla.-based Aurora Diagnostics is one of the largest independent anatomic pathology labs in the United States, with 110 physicians on staff. Its previous service agreement with NeoGenomics was regional in basis and much smaller than the current pact, said NeoGenomics Chief Executive Officer Douglas Van Oort. NeoGenomics specializes in oncology testing. Earlier this year, it launched nearly two dozen new tests focused on the genetic sequencing and treatment development of a variety of hematological and solid tumor cancers. The annualized value of the deal with Aurora and the projected test volumes were not disclosed. Takeaway: NeoGenomics continues to expand its testing business […]